Author

Sarah Harris

THE EFFECT OF OZANIMOD ON CIRCULATING NEUTROPHILS: RESULTS FROM THE TRUE NORTH STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
THE EFFECT OF OZANIMOD ON CIRCULATING NEUTROPHILS: RESULTS FROM THE TRUE NORTH STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Sarah Harris  et al.

IMPACT OF OZANIMOD (OZA) ON INTERLEUKIN-17A (IL-17A) LEVELS AND THE ASSOCIATION WITH OZA EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC): RESULTS FROM THE PHASE 3 TRUE NORTH (TN) STUDY
IMPACT OF OZANIMOD (OZA) ON INTERLEUKIN-17A (IL-17A) LEVELS AND THE ASSOCIATION WITH OZA EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC): RESULTS FROM THE PHASE 3 TRUE NORTH (TN) STUDY

Sarah Harris  et al.

ASSOCIATION OF NONSWITCHED MEMORY B-CELL (MBC) LEVELS WITH OZANIMOD (OZA) EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE (CD): RESULTS FROM THE PHASE 2 STEPSTONE STUDY
ASSOCIATION OF NONSWITCHED MEMORY B-CELL (MBC) LEVELS WITH OZANIMOD (OZA) EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE (CD): RESULTS FROM THE PHASE 2 STEPSTONE STUDY

Sarah Harris  et al.

THE EFFECT OF OZANIMOD ON CIRCULATING NEUTROPHILS: RESULTS FROM THE TRUE NORTH STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
THE EFFECT OF OZANIMOD ON CIRCULATING NEUTROPHILS: RESULTS FROM THE TRUE NORTH STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

IMPACT OF OZANIMOD (OZA) ON C-REACTIVE PROTEIN (CRP) LEVELS AND THE ASSOCIATION WITH OZA EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC): RESULTS FROM THE PHASE 3 TRUE NORTH (TN) STUDY
IMPACT OF OZANIMOD (OZA) ON C-REACTIVE PROTEIN (CRP) LEVELS AND THE ASSOCIATION WITH OZA EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC): RESULTS FROM THE PHASE 3 TRUE NORTH (TN) STUDY

Sarah Harris  et al.

IMPACT OF OZANIMOD ON FECAL CALPROTECTIN LEVELS AND THE ASSOCIATION WITH OZANIMOD EFFICACY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 TRUE NORTH STUDY
IMPACT OF OZANIMOD ON FECAL CALPROTECTIN LEVELS AND THE ASSOCIATION WITH OZANIMOD EFFICACY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 TRUE NORTH STUDY

ASSOCIATION BETWEEN ABSOLUTE LYMPHOCYTE COUNT AND OZANIMOD EFFICACY AND SAFETY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 TRUE NORTH STUDY
ASSOCIATION BETWEEN ABSOLUTE LYMPHOCYTE COUNT AND OZANIMOD EFFICACY AND SAFETY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 TRUE NORTH STUDY

EFFECTS OF OZANIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: FLOW CYTOMETRY RESULTS FROM THE STEPSTONE PHASE 2 STUDY
EFFECTS OF OZANIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: FLOW CYTOMETRY RESULTS FROM THE STEPSTONE PHASE 2 STUDY

Sarah Harris  et al.

IMPACT OF OZANIMOD ON FECAL CALPROTECTIN LEVELS AND THE ASSOCIATION WITH OZANIMOD EFFICACY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 TRUE NORTH STUDY
IMPACT OF OZANIMOD ON FECAL CALPROTECTIN LEVELS AND THE ASSOCIATION WITH OZANIMOD EFFICACY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 TRUE NORTH STUDY

Sarah Harris  et al.

ASSOCIATION BETWEEN ABSOLUTE LYMPHOCYTE COUNT AND OZANIMOD EFFICACY AND SAFETY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 TRUE NORTH STUDY
ASSOCIATION BETWEEN ABSOLUTE LYMPHOCYTE COUNT AND OZANIMOD EFFICACY AND SAFETY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 TRUE NORTH STUDY

Sarah Harris  et al.

ANTI–IL-13 (CENDAKIMAB) ADMINISTRATION IMPROVES OESOPHAGEAL GENE EXPRESSION IN EOSINOPHILIC OESOPHAGITIS
ANTI–IL-13 (CENDAKIMAB) ADMINISTRATION IMPROVES OESOPHAGEAL GENE EXPRESSION IN EOSINOPHILIC OESOPHAGITIS

Sarah Harris  et al.

OZANIMOD EFFICACY BY BASELINE ENDOSCOPIC DISEASE DISTRIBUTION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: A POST HOC ANALYSIS FROM TRUE NORTH
OZANIMOD EFFICACY BY BASELINE ENDOSCOPIC DISEASE DISTRIBUTION IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS: A POST HOC ANALYSIS FROM TRUE NORTH

Sarah Harris  et al.

OZANIMOD IS AN EFFECTIVE ORAL TREATMENT FOR PATIENTS WITH ULCERATIVE COLITIS REGARDLESS OF MODERATE OR SEVERE ENDOSCOPIC DISEASE ACTIVITY: A POST HOC ANALYSIS OF TRUE NORTH
OZANIMOD IS AN EFFECTIVE ORAL TREATMENT FOR PATIENTS WITH ULCERATIVE COLITIS REGARDLESS OF MODERATE OR SEVERE ENDOSCOPIC DISEASE ACTIVITY: A POST HOC ANALYSIS OF TRUE NORTH

Sarah Harris  et al.

Item 1 - 13 / 13
1